Outcome of early vs. deferred antiviral treatment for recurrent hepatitis C in liver transplant recipients
Journal Title: Annals of Hepatology - Year 2014, Vol 13, Issue 2
Abstract
The optimal timing to treat recurrent hepatitis-C virus (HCV) after liver transplantation (LT) remains uncertain. We compared the outcome of early (acute phase) and deferred (chronic phase) antiviral treatment for recurrent HCV infection in this population. Consecutive HCV genotype-1 infected LT patients receiving antiviral therapy between 2001-2010 were retrospectively classified according to histology at treatment start into the early or deferred treatment group. Measured endpoints included sustained virological response (SVR) rates and long-term survival. The study cohort comprised 105 patients: 60 (57%) received early treatment (ET) and 45 (43%) deferred treatment (DT). The median interval from LT to antiviral start was 3 (1-9) and 18 months (11-74) in ET and DT respectively. The SVR rate was similar in both treatment groups (23% ET and 36% DT; p = 0.27). After a median follow-up of 5.8 years, all-cause and liver-related mortality were similar in both groups. Variables independently associated with mortality included pre-treatment bilirubin > 2 mg/dL (HR 6.1, 95%CI: 2.8-13.7; p < 0.001), donor age > 60 (HR 3.1, 95%CI: 1.4-6.7; p = 0.01), and failure to achieve SVR (HR 10.3, 95%CI: 1.3-18.3; p = 0.03). In conclusion, early treatment of recurrent HCV is safe, but does not lead to higher SVR rates. In HCV-infected LT recipients, elevated bilirubin, older donor age, and failure to achieve SVR are independently associated with increased mortality.
Authors and Affiliations
Isabel Campos-Varela, Juan Ignacio Esteban, Marta Bes, Cristina Dopazo, Helena Allende, Francisco Rodríguez-Frías, María Teresa Salcedo, Silvia Sauleda, Ramón Charco, Jaime Guardia, Rafael Esteban, Lluis Castells
Keywords
Related Articles
- EP ID EP78378
- DOI -
- Views 132
- Downloads 0
Distribution of HCV genotypes and HCV RNA viral load in different regions of Mexico
Background and aim. To identify the geographic distribution of hepatitis C virus (HCV) genotypes and HCV RNA viral load in a large number of HCV-infected carriers in Mexico. Methods. Patients with chronic hepatitis C (n...
Acute kidney injury in critically ill cirrhotic patients: a review
Acute kidney injury (AKI) is an important marker of morbidity and mortality in critically ill cirrhotic patients. The most common causes of AKI in cirrhotic patients include prerenal or hepatorenal syndrome...
Fulminant hepatitis during self-medication with conjugated linoleic acid
The present report describes a 63-year-old female who presented with fulminant hepatic failure requiring liver transplantation caused by a weight loss dietary supplement containing conjugated linoleic acid (CLA). Thoroug...
Incisional intercostal hernia with prolaps of the liver
Peginterferon alpha-2b plus ribavirin for chronic hepatitis C virus mixed genotype infection
Background and aim. The treatment efficacy of peginterferon plus ribavirin for patients with HCV genotype 1 is inferior to that in patients with HCV genotype 2, but the efficacy among patients with mixed HCV genotype 1 +...